Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KFA115 as a Single Agent and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2022
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 1, open-label trial of KFA115 in non-small cell lung cancer (NSCLC), cutaneous melanoma (CM), renal cell carcinoma (RCC) and 9 more (3 arms), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events and Serious Adverse Events at 35 months and 2 more. Started Oct 2022; status: active, not recruiting.
02
Drugs
KFA115
03
Conditions
non-small cell lung cancer (NSCLC)cutaneous melanoma (CM)renal cell carcinoma (RCC)ovarian epithelial carcinomanasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05544929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05544929.